Develops drug candidates for neurological, cancer, respiratory and metabolic diseases, seeking pharmaceutical partners to help complete development and commercialize them.
10-K for FY2025, filed Mar 10, 2026
Mayo Foundation for Medical Education and Research contracts for clinical research and pharmacovigilance support; the company expects to rely on strategic partners to commercialize products.
10-K for FY2025, filed Mar 10, 2026
No. It lost $12M in FY2025.
A narrower stated development focus
The earlier overview also included addiction, an asthma candidate, a solid-tumor candidate, and idiopathic pulmonary fibrosis; the latest strategy instead centers on ibudilast and tipelukast for neurological, respiratory, cancer, fibrotic and metabolic conditions.
10-K for FY2022, filed Feb 16, 2023 10-K for FY2025, filed Mar 10, 2026We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs…View ↗
We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs…View ↗
Competes with Sanofi, Roche, AB Science, BrainStorm Cell Therapeutics, Ionis Pharmaceuticals, Clene, Kazia Therapeutics, Kintara Therapeutics, Denovo Biopharma, Laminar Pharmaceuticals, TVAX Biomedical, Madrigal Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Galmed Pharmaceuticals, Pfizer, Novo Nordisk, and Merck
10-K for FY2025, filed Mar 10, 2026Our MN-166 (ibudilast) product candidate is in development for the treatment of progressive MS. Mitoxantrone is approved for the treatment…View ↗
Loading...